Iran is pushing boundaries amid rising tensions in the Gulf, but President Trump has so far not been "compelled" to retaliate militarily, analysts say.World Politicsread more
The deal could be announced as soon as next week, according to the report.Technologyread more
The deal between the White House and Democrats was earlier expected to raise the debt ceiling for two years and permanently end the sequester.Politicsread more
The U.K. will find out who its next prime minister will be on Tuesday.Europe Politicsread more
UBS announced a net profit of $1.4 billion for the second quarter of 2019.Earningsread more
Japan and South Korea are part of a complex and tightly linked supply chain that produces electronic goods such as smartphones and laptops.Technologyread more
Michael Kugelman from the U.S.-based Wilson Center says other issues take precedence in the bilateral dialogue between the United States and Pakistan — namely, Afghanistan and...Asia Politicsread more
Beijing says it can still meet its 2019 growth target of between 6% and 6.5% and continues to roll out stimulus measures to prop up activity. China set a 2019 industrial...China Economyread more
A different oil pricing dynamic has been evolving with new supply calculations based on the U.S. as the world's largest producer.Market Insiderread more
The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Stocks in Asia Pacific edged up on Tuesday, as investors await closely-watched central bank meetings in the coming days.Asia Marketsread more
Spinal muscular atrophy (SMA) is the leading cause of infantile death worldwide. Ionis CEO Dr. Stanley Crooke spoke with Jim Cramer on Monday, and estimated 30,000 infants around the world are born with SMA.
The drug could potentially be a $2 billion franchise, which is much higher than previous estimates, according to analysts. Ionis could receive royalties from those sales in the mid-teens, as well as $150 million in milestone payments from Biogen if everything goes well. This is in addition to the $75 million license fee that Biogen just paid Ionis.
"You can easily come to the notion of a very large commercial opportunity," Crooke said. "Obviously that's Biogen's area of responsibility, and so I won't be able to comment further, other than we believe this is an enormous commercial opportunity."
With positive study results, Crooke expects Ionis to be able to move forward aggressively to bring the study to an end. This will ensure that babies in the control arm can now receive Nusinersen. He said it is very important that Biogen's planned broad access program will allow babies to access Nusinersen earlier than they would if they had to wait to finish the trial.
"I think that the results that we reported are truly remarkable," Crooke said.
Ionis changed its name from Isis Pharmaceuticals late last year, and has pioneered antisense technology, which allows it to create drugs that target cells' RNA. Cramer described RNA as the biological equivalent of middle management: the DNA gives cells orders, and RNA carries those orders to the rest of the cell. Thus, if the message to the RNA is altered, it can fix many problems.
Initially investors were very excited about the 38 drugs in Ionis's pipeline. However, many biotech stocks went out of favor with political worries on drug prices and took Ionis down with them. The stock declined even further in May when GlaxoSmithKline said it would not be moving forward with phase 3 trials on a cardiomyopathy drug it had partnered with Ionis on.
"While the company has made a lot of missteps in the past year, there are a lot of drugs in the pipeline that could potentially pay off," the "Mad Money " host said.